Dare Bioscience (NASDAQ:DARE) Shares Up 4.3%

Dare Bioscience Inc (NASDAQ:DARE) shares shot up 4.3% on Thursday . The stock traded as high as $1.69 and last traded at $1.62, 1,980,229 shares traded hands during mid-day trading. A decline of 42% from the average session volume of 3,394,085 shares. The stock had previously closed at $1.55.

A number of brokerages have recently commented on DARE. ValuEngine lowered Dare Bioscience from a “hold” rating to a “sell” rating in a report on Wednesday. Maxim Group restated a “buy” rating and set a $3.00 price objective on shares of Dare Bioscience in a research report on Tuesday, November 12th.

The business has a 50-day simple moving average of $0.86 and a two-hundred day simple moving average of $0.82. The stock has a market capitalization of $22.86 million, a P/E ratio of -1.51 and a beta of 1.86.

Dare Bioscience (NASDAQ:DARE) last announced its quarterly earnings results on Thursday, November 14th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.01. Sell-side analysts anticipate that Dare Bioscience Inc will post -0.99 earnings per share for the current year.

An institutional investor recently raised its position in Dare Bioscience stock. Susquehanna International Group LLP grew its holdings in Dare Bioscience Inc (NASDAQ:DARE) by 293.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 42,770 shares of the biotechnology company’s stock after acquiring an additional 31,900 shares during the quarter. Susquehanna International Group LLP owned 0.26% of Dare Bioscience worth $36,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 4.82% of the company’s stock.

Dare Bioscience Company Profile (NASDAQ:DARE)

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

Further Reading: How Do You Calculate Return on Equity (ROE)?

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.